Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aumolertinib”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06463171
What this trial is testing

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Shanghai Pulmonary Hospital, Shanghai, China 60
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Early research (Phase 1)Looking for participantsNCT06926413
What this trial is testing

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Looking for participantsNCT04841811
What this trial is testing

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 192
Testing effectiveness (Phase 2)Looking for participantsNCT06951464
What this trial is testing

BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan University 40
Testing effectiveness (Phase 2)UnknownNCT04755738
What this trial is testing

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
Qianfoshan Hospital 234
Large-scale testing (Phase 3)Looking for participantsNCT06043973
What this trial is testing

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Who this might be right for
Advanced Non-small Cell Lung Cancer
Qianfoshan Hospital 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Testing effectiveness (Phase 2)UnknownNCT04636593
What this trial is testing

Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation
First People's Hospital of Hangzhou 43
Early research (Phase 1)UnknownNCT05826483
What this trial is testing

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Who this might be right for
Malignant Tumor of LungPoor Performance Status
Guangzhou Institute of Respiratory Disease 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04685070
What this trial is testing

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Stage III
Shanghai Pulmonary Hospital, Shanghai, China 56
Testing effectiveness (Phase 2)UnknownNCT04643847
What this trial is testing

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Who this might be right for
EGFR Positive Non-small Cell Lung CancerBrain Metastases
First People's Hospital of Hangzhou 47
Testing effectiveness (Phase 2)Looking for participantsNCT06300424
What this trial is testing

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Guangdong Provincial People's Hospital 32
Large-scale testing (Phase 3)Looking for participantsNCT05768490
What this trial is testing

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Who this might be right for
Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University 232
Testing effectiveness (Phase 2)UnknownNCT04455594
What this trial is testing

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIA
The First Affiliated Hospital of Guangzhou Medical University 168
Early research (Phase 1)UnknownNCT05223595
What this trial is testing

Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. 42
Not applicableUnknownNCT04944069
What this trial is testing

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Who this might be right for
NSCLCLeptomeningeal MetastasisEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 69
Testing effectiveness (Phase 2)UnknownNCT04785729
What this trial is testing

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Who this might be right for
Safety
Sun Yat-sen University 36
Large-scale testing (Phase 3)Looking for participantsNCT06417008
What this trial is testing

HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company 1,080
Testing effectiveness (Phase 2)UnknownNCT05810350
What this trial is testing

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Who this might be right for
Non-small Cell Lung Cancer
Three Gorges Hospital of Chongqing University 40
Load More Results